Cargando…

Tissue factor activity on microvesicles from cancer patients

PURPOSE: The expression of active tissue factor (TF) on the surface of microvesicles (MVs) is essential for the activation of the coagulation system and transduction of the signaling pathways in cancer cells. In its use as a biomarker for cancer-associated venous thromboembolism (VTE), TF has shown...

Descripción completa

Detalles Bibliográficos
Autores principales: Ender, Fanny, Freund, Annika, Quecke, Tabea, Steidel, Corinna, Zamzow, Piet, von Bubnoff, Nikolas, Gieseler, Frank
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6985086/
https://www.ncbi.nlm.nih.gov/pubmed/31734835
http://dx.doi.org/10.1007/s00432-019-03073-0
_version_ 1783491745451868160
author Ender, Fanny
Freund, Annika
Quecke, Tabea
Steidel, Corinna
Zamzow, Piet
von Bubnoff, Nikolas
Gieseler, Frank
author_facet Ender, Fanny
Freund, Annika
Quecke, Tabea
Steidel, Corinna
Zamzow, Piet
von Bubnoff, Nikolas
Gieseler, Frank
author_sort Ender, Fanny
collection PubMed
description PURPOSE: The expression of active tissue factor (TF) on the surface of microvesicles (MVs) is essential for the activation of the coagulation system and transduction of the signaling pathways in cancer cells. In its use as a biomarker for cancer-associated venous thromboembolism (VTE), TF has shown high expression variability. As a contribution to this discussion, we present a study investigating plasma samples from patients with various progressive tumors at high risk for VTE. METHODS: Based on our previous study uncovering microvesicles (MVs), the larger ectosome-like extracellular vesicles (EV), as the major source of TF activity in EV preparations, we now determined TF activity on enriched MVs isolated from plasma of cancer patients and compared it with that on MVs from healthy individuals. RESULTS: We found considerably higher amounts of MVs as well as higher levels of MV-bound TF activities in the plasma of cancer patients. We also show that preparations from plasma of cancer patients have the potency to induce ERK phosphorylation in a human tumor cell line through proteinase-activated receptor two (PAR2) activation. CONCLUSION: We suggest that MVs instead of whole EV preparations, and TF activity rather than its antigenic quantification should be used in clinical studies for identifying patients with progressive tumors at high risk for VTE. GRAPHIC ABSTRACT: [Image: see text] ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1007/s00432-019-03073-0) contains supplementary material, which is available to authorized users.
format Online
Article
Text
id pubmed-6985086
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Springer Berlin Heidelberg
record_format MEDLINE/PubMed
spelling pubmed-69850862020-02-07 Tissue factor activity on microvesicles from cancer patients Ender, Fanny Freund, Annika Quecke, Tabea Steidel, Corinna Zamzow, Piet von Bubnoff, Nikolas Gieseler, Frank J Cancer Res Clin Oncol Original Article – Clinical Oncology PURPOSE: The expression of active tissue factor (TF) on the surface of microvesicles (MVs) is essential for the activation of the coagulation system and transduction of the signaling pathways in cancer cells. In its use as a biomarker for cancer-associated venous thromboembolism (VTE), TF has shown high expression variability. As a contribution to this discussion, we present a study investigating plasma samples from patients with various progressive tumors at high risk for VTE. METHODS: Based on our previous study uncovering microvesicles (MVs), the larger ectosome-like extracellular vesicles (EV), as the major source of TF activity in EV preparations, we now determined TF activity on enriched MVs isolated from plasma of cancer patients and compared it with that on MVs from healthy individuals. RESULTS: We found considerably higher amounts of MVs as well as higher levels of MV-bound TF activities in the plasma of cancer patients. We also show that preparations from plasma of cancer patients have the potency to induce ERK phosphorylation in a human tumor cell line through proteinase-activated receptor two (PAR2) activation. CONCLUSION: We suggest that MVs instead of whole EV preparations, and TF activity rather than its antigenic quantification should be used in clinical studies for identifying patients with progressive tumors at high risk for VTE. GRAPHIC ABSTRACT: [Image: see text] ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1007/s00432-019-03073-0) contains supplementary material, which is available to authorized users. Springer Berlin Heidelberg 2019-11-16 2020 /pmc/articles/PMC6985086/ /pubmed/31734835 http://dx.doi.org/10.1007/s00432-019-03073-0 Text en © The Author(s) 2019 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.
spellingShingle Original Article – Clinical Oncology
Ender, Fanny
Freund, Annika
Quecke, Tabea
Steidel, Corinna
Zamzow, Piet
von Bubnoff, Nikolas
Gieseler, Frank
Tissue factor activity on microvesicles from cancer patients
title Tissue factor activity on microvesicles from cancer patients
title_full Tissue factor activity on microvesicles from cancer patients
title_fullStr Tissue factor activity on microvesicles from cancer patients
title_full_unstemmed Tissue factor activity on microvesicles from cancer patients
title_short Tissue factor activity on microvesicles from cancer patients
title_sort tissue factor activity on microvesicles from cancer patients
topic Original Article – Clinical Oncology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6985086/
https://www.ncbi.nlm.nih.gov/pubmed/31734835
http://dx.doi.org/10.1007/s00432-019-03073-0
work_keys_str_mv AT enderfanny tissuefactoractivityonmicrovesiclesfromcancerpatients
AT freundannika tissuefactoractivityonmicrovesiclesfromcancerpatients
AT quecketabea tissuefactoractivityonmicrovesiclesfromcancerpatients
AT steidelcorinna tissuefactoractivityonmicrovesiclesfromcancerpatients
AT zamzowpiet tissuefactoractivityonmicrovesiclesfromcancerpatients
AT vonbubnoffnikolas tissuefactoractivityonmicrovesiclesfromcancerpatients
AT gieselerfrank tissuefactoractivityonmicrovesiclesfromcancerpatients